STOCK TITAN

Neuropace Inc - NPCE STOCK NEWS

Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.

NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.

Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.

Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions

Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.

Rhea-AI Summary

NeuroPace, Inc. (NPCE) reported total revenue of $18.1 million in Q1 2024, a 25% increase from Q1 2023. The company extended its term loan maturity, maintained full-year revenue guidance of $73 to $77 million, and achieved growth in RNS System and DIXI Medical sales. Operating expenses were managed effectively, resulting in decreased losses compared to the prior year. The company remains focused on expanding market reach and increasing access to RNS therapy for epilepsy patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.75%
Tags
-
Rhea-AI Summary
NeuroPace, a medical device company specializing in epilepsy treatment, will release its first-quarter 2024 financial results on May 8, 2024. The management will host a conference call for investors to discuss the results. Interested parties can access the live webcast or participate via telephone. The webcast will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences earnings
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at the Needham 23rd Annual Healthcare Conference. CEO Joel Becker to provide a corporate presentation on April 8. The company focuses on epilepsy treatment and will engage in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences
Rhea-AI Summary
NeuroPace, Inc. (NPCE) reported a 41% increase in revenue to $18.0 million in Q4 2023 compared to Q4 2022, a 44% increase to $65.4 million in 2023 over 2022. The company provided a revenue guidance of $73-$77 million for 2024. Initiatives like Project CARE and the NAUTILUS study show strategic growth plans. Gross margin increased to 75.2% in Q4 2023. Operating expenses were effectively managed, resulting in a reduced cash burn of $3.4 million in Q4 2023. Full-year 2023 revenue grew 44% to $65.4 million, with a focus on RNS System sales and DIXI Medical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to Report Q4 and Full Year 2023 Financial Results on March 5, 2024. The company will host a conference call for investors to discuss the results. Webcast and call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences earnings
-
Rhea-AI Summary
NeuroPace, Inc. (NPCE) expects Q4 2023 revenue between $17.5-18.0 million, with full-year 2023 revenue between $64.9-65.4 million. The company also announced a cash balance of $66.5 million and completed milestones in patient implant, data collaboration, and a pilot program. The NAUTILUS trial for epilepsy treatment is progressing ahead of schedule. The company's CEO expressed satisfaction with 2023 accomplishments and optimism for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.89%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) completes patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule. The RNS System could secure the first device-based indication for generalized epilepsy, addressing the treatment gap for the 1.2 million drug refractory epilepsy patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) announced a strategic collaboration with a clinical-stage biotechnology company to leverage RNS System’s unique biomarker monitoring and data analysis capabilities. The collaboration involves tracking responses of implanted RNS System patients enrolled in the biotechnology company’s clinical trial. NeuroPace will receive up to $3.7 million over two years for providing non-exclusive access to its proprietary biomarker monitoring and data analysis capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) will have a substantial presence at the 77th American Epilepsy Society Annual Meeting, featuring over 50 scientific presentations and posters regarding the RNS System, a therapy option for drug resistant epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Neuropace Inc

Nasdaq:NPCE

NPCE Rankings

NPCE Stock Data

351.32M
23.73M
3.38%
61.73%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW